Today: 23 May 2026
Browse Category

NYSE:LLY 23 February 2026 - 11 May 2026

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health reports first-quarter results Monday after the market close, with Wall Street expecting about $617 million in revenue and EPS of 3 to 4 cents. Investors are watching whether its weight-loss business can grow after it stopped broadly marketing compounded GLP-1 drugs and shifted to FDA-approved options from Novo Nordisk. Hims shares closed at $28.46 Friday, rising to $29.07 after hours.
11 May 2026
····
Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk raised its 2026 outlook after early U.S. sales of its new Wegovy weight-loss pill surpassed 2 million prescriptions since January, beating expectations. Shares jumped as much as 9.2% in Copenhagen. Adjusted first-quarter sales fell 10% to 70.06 billion crowns, but reported net sales rose 24% to 96.82 billion crowns after a U.S. drug pricing provision reversal.
6 May 2026
···
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
30 April 2026
··
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.
21 April 2026
·····
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront, expanding into experimental cell therapies for blood cancer. Kelonia’s KLN-1010, in Phase 1 trials for multiple myeloma, uses in-body CAR-T technology. Lilly shares rose 2.5% after the announcement. The deal follows Lilly’s recent acquisitions as it seeks growth beyond obesity drugs.
20 April 2026
·
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly secured a global licensing and research deal with Insilico Medicine worth up to $2.75 billion, including $115 million upfront. Lilly’s shares closed Friday at $878.24, down 2.1%. The company also reported positive late-stage results for Taltz with Zepbound in psoriatic arthritis and for eczema drug Ebglyss. Novo Nordisk launched a rival oral obesity pill in the U.S. earlier this month.
29 March 2026
··
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly shares fell 1% Tuesday to $1,007.73, extending losses ahead of an FDA decision on its oral obesity pill expected in April. Ventyx Biosciences shareholders approved a merger with Lilly, with Nasdaq set to halt Ventyx stock after hours Tuesday and the deal expected to close before Wednesday’s open. The FDA issued warning letters to 30 telehealth firms over ads for compounded weight-loss drugs.
4 March 2026
···
Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.
2 March 2026
····
Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly shares rose 2.93% to $1,051.99 Friday, breaking a three-day slide after new trial data on its oral obesity pill orforglipron. The pill showed more side effects and drop-outs than Novo Nordisk’s rival, with 58% of patients on the higher dose reporting gastrointestinal issues. An FDA decision on orforglipron is expected in April. Lilly’s next earnings call is scheduled for April 30.
28 February 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
1 2 3 … 12

Stock Market Today

  • Vanguard S&P 500 ETF (VOO) Stands Out for Decade-Long AI-Driven Growth Potential
    May 22, 2026, 9:04 PM EDT. The Vanguard S&P 500 ETF (VOO) offers low-cost exposure to roughly 500 of America's largest companies, with an expense ratio of just 0.03%, significantly below the category average. The fund's heavy concentration in top technology giants like Nvidia, Apple, Microsoft, Amazon, and Alphabet, which make up about 25% of assets, provides meaningful exposure to AI and cloud computing growth sectors. VOO's structure benefits from Vanguard's unique investor-owned model, helping keep costs down and capital gains distributions minimized, enhancing long-term returns. With net assets nearing $1 trillion, fueled by $100 billion inflows in 2025, VOO remains a top choice for investors seeking a single, broad-market ETF poised to capitalize on the evolving digital economy over the next decade.

Latest articles

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

Dow Hits Record Close; All Eyes Turn to Holiday-Week Trading

23 May 2026
The Dow closed at a record 50,579.70 on Friday, while the S&P 500 notched its eighth straight weekly gain. After-hours trading saw SPY, QQQ, DIA, and IWM all move lower. U.S. markets will be closed Monday for Memorial Day. Investors await Thursday’s inflation data.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

23 May 2026
IREN shares fell 2.1% to $56.83 Friday, ending a two-day rally but closing the week up 7.4%. The stock’s moves follow a $3.4 billion AI cloud deal with Nvidia and a $3 billion convertible note offering. March-quarter revenue dropped to $144.8 million, with a net loss of $247.8 million. U.S. markets close Monday for Memorial Day; trading resumes Tuesday.
AXT stock reaches record; investors weigh risk to rally

AXT stock reaches record; investors weigh risk to rally

23 May 2026
AXT shares jumped 16.37% to $140.83 on Friday, hitting a 52-week high and trading above all recent analyst targets. The surge followed strong demand for AI-linked optical networking hardware and a sharp rise in indium phosphide orders. First-quarter revenue climbed to $26.9 million, with gross margin turning positive. Management forecast Q2 profitability and a backlog over $100 million.
Go toTop